Teniposide

Teniposide

Clinical data
Trade names	Vumon
AHFS/Drugs.com	Monograph
MedlinePlus	a692045
Pregnancy category	AU: D US: D (Evidence of risk)
Routes of administration	Intravenous
ATC code	L01CB02 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	N/A
Protein binding	>99%
Metabolism	Hepatic (CYP2C19-mediated)
Biological half-life	5 hours
Excretion	Renal and fecal
Identifiers
IUPAC name (5R,5aR,8aR,9S)-5,8,8a,9-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-({4,6-O-[(R)-2-thienylmethylene]-β-D-glucopyranosyl}oxy)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
Synonyms	VM-26
CAS Number	29767-20-2 Y
PubChem CID	34698
IUPHAR/BPS	6843
DrugBank	DB00444 N
ChemSpider	31930 N
UNII	957E6438QA
KEGG	D02698 Y
ChEBI	CHEBI:75988 N
ChEMBL	CHEMBL1200536 N
ECHA InfoCard	100.045.286
Chemical and physical data
Formula	C32H32O13S
Molar mass	656.655 g/mol
3D model (Jmol)	Interactive image
SMILES COc1cc(cc(c1O)OC)[C@@H]2c3cc4c(cc3[C@H]([C@@H]5[C@@H]2C(=O)OC5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)COC(O7)c8cccs8)O)O)OCO4
InChI InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31?,32-/m0/s1 N Key:NRUKOCRGYNPUPR-PSZSYXFXSA-N N
NY (what is this?)

Teniposide (trade name Vumon) is a chemotherapeutic medication used in the treatment of childhood acute lymphocytic leukemia (ALL), Hodgkin's lymphoma, certain brain tumours, and other types of cancer. It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body.

Teniposide is used for the treatment of a number of cancer types in children. In the US, it is approved for the second-line therapy of acute lymphocytic leukemia (ALL) in combination with other antineoplastic drugs. In Europe, it is also approved for the treatment of Hodgkin's lymphoma, generalized malignant lymphoma, reticulocyte sarcoma, acute leukaemia, primary brain tumours (glioblastoma, ependymoma, astrocytoma), bladder cancer, neuroblastoma and other solid tumours in children.

The medication is injected though a vein and burns if it leaks under the skin. It can be used in combination with other anticancer drugs.

The drug is contraindicated during pregnancy and lactation, in patients with severe liver or kidney impairment or severely impaired haematopoiesis.

Teniposide, when used with other chemotherapeutic agents for the treatment of ALL, results in severe bone marrow suppression. Other common side effects include gastrointestinal toxicity, hypersensitivity reactions, and reversible alopecia.